PI Industries announces Twin Acquisitions into Pharma API & CDMO space

PI Industries' acquisitions of Archimica S.p.A and Therachem strengthen its global Pharma presence. These acquisitions make PI Health Sciences a comprehensive one-stop solution provider in the pharmaceutical industry, offering CRO solutions, CDMO solutions, and KSM/API solutions. 

PI Health Sciences Netherlands B.V, a wholly owned subsidiary of PI Health Sciences Limited, India (PIHS) has acquired 100% Equity of Archimica S.p.A, a leading pharmaceutical company having a cGMP manufacturing facility in Lodi, Italy. The acquisition of Archimica S.p.A will enable PIHS to broaden its portfolio of APIs and expand its reach in the European market.

PIHS through its wholly owned subsidiary in the US, PI Health Sciences USA LLC, has also signed a definitive agreement to acquire 100% Equity of Therachem (Therachem India & Solis Pharmachem) and certain assets of Therachem USA, which is engaged in the manufacturing of intermediates and non-GMP APIs for pre-clinical and clinical studies. PIHS (USA) will be the front-end arm for customer relationships in the USA. PIHS will offer services and products in Medicinal Chemistry and Drug Discovery with its two manufacturing facilities in Jaipur and Ankleshwar in India.

With these twin acquisitions into Pharma API & CDMO space, PIHSL would be a one-stop solution provider including  CRO solutions, CDMO solutions and KSM/API solutions.

PI Health Sciences Ltd. is a wholly owned subsidiary of PI Industries Ltd. (“PI”). Incorporated in 1947, PI Industries (BSE: 523642, NSE: PIIND, ISIN ID: INE603J01030) envisions to be at the forefront of science-led opportunities by delivering innovative solutions. PI Industries’ core values of trust, adaptability, speed, and innovation enable them to deliver the highest value to its customers and respect IP of its partners. With a strength of over 3,500 employees, the Company currently operates a strong infrastructure set-up consisting of 3 formulation facilities as well as 15 multi-product plants under its 4 manufacturing locations in India. PI is among the Top 100 listed companies in India with a market capitalization of over €5.0 billion. It is a Zero-debt company with 9-month revenue for year-till-date 31-Dec-22 of ~€550 million and net worth as of 31-Dec-22 of ~€770 million.

PI aims to create a differentiated position in the pharmaceuticals sector by leveraging its core competencies in complex chemistry, process development, operational excellence, technology platforms and global reach through partnerships with prominent innovators.

This acquisition marks a significant milestone in PI’s company growth strategy and is a testament to PI’s commitment to delivering innovative solutions to clients across the world.